Drug EfficacyFor patients already taking SGLT2 inhibitors, the study found no statistically significant benefit in the experimental group.
Regional PerformanceNorth America saw only a 2% benefit versus the placebo group, whereas Europe (39%) and Other geographies recorded significantly higher benefits that drove headline results.
Sales VolumeSame store vols were +0.4% y/y, decelerating from +0.7% y/y in 4Q23, despite the extra day from leap year.